BASEL, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dieter Weinand, former Chair and CEO of Bayer...
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
BASEL, Switzerland, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Anaveon, a clinical-stage immuno-oncology company, today announces updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective interleukin-2 (IL-2) agonist, in poster presentations at the European Society for Medical Oncology (ESMO) Congress 2022, taking place in Paris, September 9 – 13, 2022.
- ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...
The two Big Pharmas, alongside investment firms, came together to back the Swiss biotech's series B, which is expected to close before year's end at 114 million Swiss Franc ($119 million), Anaveon said Thursday. The financing builds upon the biotech's pre-pandemic $35 million series A from February 2019.